Congruence Therapeutics
PrivateLast Round
VC Round
Mar 19, 2026
Total Funding Raised
$98M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Congruence Therapeutics is a biotechnology company that develops small molecule correctors to rescue aberrant protein function in protein misfolding diseases using a proprietary computational drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Congruence Therapeutics Comparables
Compare Congruence Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gain Therapeutics Inc | 80% | |
| Atlas Molecular Pharma | 79% | |
| Protego Biopharma | 79% |
Congruence Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 19, 2026 | ||||
| Early Funding | Sep 4, 2025 | ||||
| Grant | Jul 24, 2025 | ||||
| Series A Extension | Mar 6, 2023 | ||||
| Series A | Feb 8, 2022 |
Key People
Founding team and executive leadership
Congruence Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Early Funding, Series A, VC Round, Series A Extension |
| Amplitude Ventures | Early Funding, VC Round, Series A Extension, Series A |
| Fonds de solidarité FTQ | Early Funding, VC Round, Series A Extension, Series A |
| BDC Capital | Early Funding, VC Round |
| OrbiMed | Early Funding, Series A, VC Round, Series A Extension |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Alexandria Venture Investments | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2026
Attending the 25th Annual Needham Virtual Healthcare Conference.
- Apr 8, 2026
Launched Revenir™ for identifying novel binding sites.
Congruence Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Congruence Therapeutics's valuation, stock price, and market status.
Is Congruence Therapeutics a public or private company?
Congruence Therapeutics is a private company.
What is the current stock price of Congruence Therapeutics?
Congruence Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Congruence Therapeutics worth (valuation)?
Valuation information for Congruence Therapeutics is not publicly available.
Can I buy Congruence Therapeutics stock?
Congruence Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Congruence Therapeutics's last funding round?
Congruence Therapeutics's most recent funding round was Early Funding on March 19, 2026.
Who are the main investors in Congruence Therapeutics?
Key investors in Congruence Therapeutics include Amplitude Ventures, Fonds de solidarité FTQ, The Michael J. Fox Foundation for Parkinson's Research, BDC Capital Management, Dimension.
Will Congruence Therapeutics IPO soon?
No public IPO plans have been announced for Congruence Therapeutics.
How can I track Congruence Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Congruence Therapeutics's secondary market activity and sign up for updates.